Search research articles
Contact Us
Filters
Showing results (191-200 of 247) with videos related to
Page
of 25
Sort By:
Inflammatory Bowel Diseases
|
August 22, 2020
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States
Benjamin L Cohen, Zane R Gallinger, Christina Ha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Remo Panaccione, Marc Ferrante, Iris Dotan, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases
|
December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
Kimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Gastroenterology
|
February 15, 2017
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
Jeffrey S Hyams, Marla C Dubinsky, Robert N Baldassano, et al.
Inflammatory Bowel Diseases
|
March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Crohn'S & Colitis
|
June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases
|
May 14, 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease
Marla C Dubinsky, Subra Kugathasan, Soonil Kwon, et al.
Nature Reviews. Gastroenterology & Hepatology
|
April 22, 2025
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response
Virginia Solitano, Charles N Bernstein, Iris Dotan, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 247) with videos related to
Sort By:
Page
of 25
Inflammatory Bowel Diseases
|
August 22, 2020
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States
Benjamin L Cohen, Zane R Gallinger, Christina Ha, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Remo Panaccione, Marc Ferrante, Iris Dotan, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)
|
March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases
|
December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
Kimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.
Gastroenterology
|
February 15, 2017
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
Jeffrey S Hyams, Marla C Dubinsky, Robert N Baldassano, et al.
Inflammatory Bowel Diseases
|
March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Crohn'S & Colitis
|
June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases
|
May 14, 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease
Marla C Dubinsky, Subra Kugathasan, Soonil Kwon, et al.
Nature Reviews. Gastroenterology & Hepatology
|
April 22, 2025
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response
Virginia Solitano, Charles N Bernstein, Iris Dotan, et al.
Page
of 25